10% holder net buying at Concordia International (T:CXR)

Solus Alternative Asset Management LP, a 10% Holder, acquired 7,400 Limited Voting Shares on a control or direction basis for registered holder Certain funds and accounts managed by Solus Alternative Asset Management LP and/or subsidiaries thereof at prices ranging from $24.569 to $26.670 between November 16th, 2018 and November 19th, 2018. This represents a $181,601 net investment into the company's shares and an account share holdings change of 0.1%.

Concordia International is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company. Concordia International Corp. (CXR) has below median officer and director direct ownership compared to its mid-cap peers in the market, based on our estimate using SEDI data. According to regulatory filings yesterday, one insider has invested a net amount of $181,601.